Mineralys Therapeutics, Inc. financial data

Symbol
MLYS on Nasdaq
Location
Radnor, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2028% % 53%
Return On Equity -48% % 14%
Return On Assets -46% % 11%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 79,139,956 shares 59%
Common Stock, Shares, Outstanding 78,969,459 shares 59%
Entity Public Float $399,700,000 USD 67%
Common Stock, Value, Issued $8,000 USD 60%
Weighted Average Number of Shares Outstanding, Basic 70,594,504 shares 42%
Weighted Average Number of Shares Outstanding, Diluted 70,594,504 shares 42%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $152,176,000 USD 3%
General and Administrative Expense $31,915,000 USD 55%
Operating Income (Loss) $184,091,000 USD -9.4%
Nonoperating Income (Expense) $12,728,000 USD -16%
Net Income (Loss) Attributable to Parent $171,363,000 USD -12%
Earnings Per Share, Basic -2 USD/shares 8.9%
Earnings Per Share, Diluted -2 USD/shares 8.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $217,597,000 USD 124%
Assets, Current $599,796,000 USD 124%
Property, Plant and Equipment, Net $7,000 USD -90%
Other Assets, Noncurrent $144,000 USD -68%
Assets $599,947,000 USD 124%
Accounts Payable, Current $1,121,000 USD -64%
Accrued Liabilities, Current $22,399,000 USD -21%
Liabilities, Current $23,520,000 USD -25%
Retained Earnings (Accumulated Deficit) $424,935,000 USD -68%
Stockholders' Equity Attributable to Parent $576,427,000 USD 143%
Liabilities and Equity $599,947,000 USD 124%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $45,487,000 USD -138%
Net Cash Provided by (Used in) Financing Activities $189,279,000 USD 63%
Net Cash Provided by (Used in) Investing Activities $92,876,000 USD -66%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 78,969,459 shares 59%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $50,916,000 USD 24%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $217,597,000 USD 124%
Deferred Tax Assets, Valuation Allowance $79,929,000 USD 154%
Deferred Tax Assets, Gross $79,929,000 USD 154%
Deferred Tax Assets, Operating Loss Carryforwards $15,580,000 USD 97%
Unrecognized Tax Benefits $4,505,000 USD 319%
Additional Paid in Capital $1,001,354,000 USD 104%
Depreciation, Depletion and Amortization $15,000 USD 88%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $17,173,000 USD 78%